The EGBioMed clinical team recently held a important meeting with Dr. Yao-Yu Hsieh, Director of the Department of Hematology/Oncology at Shuang Ho Hospital. Dr. Hsieh, a leading expert in the field, has shown strong support for the recruitment of pancreatic cancer patients and the implementation of a three-month follow-up blood test as part of ongoing clinical trial.
During the meeting, Dr. Hsieh emphasized the critical need for innovative early detection tools in the fight against pancreatic cancer. He stated, “Currently, there is a significant gap in early detection tools for pancreatic cancer, making any product that can effectively identify this disease at an early stage extremely valuable in clinical practice. Our product can be incorporated into routine health checkups, allowing for initial screening. If abnormalities are detected, a follow-up CT or MRI scan can be performed, which is crucial for the early detection of pancreatic cancer.”
This collaboration underscores the importance of integrating cutting-edge diagnostic solutions into standard clinical practices to enhance early detection and improve patient outcomes in pancreatic cancer.